← board
LEGN
Nanjing Legend Biotech Co.distress 2/10 · well-funded / low risk$23.61+0%today-47% from 52w high
Immunology / Inflammation 1Oncology 1
Lead: Relapsed/Refractory Autoimmune Diseases · target BCMA
Revenue
$305M
Liquidity
$840M
Runway
8.4 yrs
Shares 1y
0%
Price & events
+22.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
+4.0%
1W
-19.4%
1M
-1.6%
3M
+24.2%
6M
-46.7%
1Y
-60.6%
2Y
-50.6%
5Y
-15.6%
All
Overview
- Market Cap
- $8.73B
- Enterprise Value
- $8.26B
- Volume
- 132.38K
- 52 Week Range
- $16.65 – $44.32
- Total Shares
- 369.89M
- Float Shares
- 86.71M
- Short %
- 16.15%
- % Held by Insiders
- 1.25%
- % Held by Institutions
- 53.93%
- RVOL
- 0.06x
- Beta
- 0.34
Pipeline stages · 2 programs
LCAR-B38M CAR-T CellBCMA
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
LUCAR-G79 T cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03-20 | Phase 1 | LUCAR-G79 T cells | Relapsed/Refractory Autoimmune Diseases | 3 | terminated |
| 2025-07-10 | Phase 2 | LCAR-B38M CAR-T Cell | Multiple Myeloma | 123 | terminated |
Catalyst news & presentations · 1
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $56 (+136% upside) · 15 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-06-03UBSBuy
- 2026-06-03HC Wainwright & Co.Buy
- 2026-05-18HC Wainwright & Co.Buy
- 2026-05-13Morgan StanleyOverweight
- 2026-05-13TD CowenHold
Competitors — BCMA
Recent news
- 2026-07-22LEGN stock holds after Legend Biotech reports 2025 revenue growth - Ad-hoc-news.de
- 2026-07-20Legend Biotech Corporation (LEGN) Investor Outlook: Unpacking the 149.93% Potential Upside - DirectorsTalk Interviews
- 2026-07-19(LEGN) Risk Channels and Responsive Allocation - Stock Traders Daily
- 2026-07-18LEGN 260618 35.00C (LEGN260618C35000) Stock Options Chain | Quotes & News - Moomoo
- 2026-07-18Legend Biotech Corporation (LEGN) Q4 2023 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-18Legend Biotech Corporation (LEGN) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-17H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65 - Moomoo
- 2026-07-17Legend Biotech (LEGN) Could Be 60% Undervalued Following CARVYKTI Sales Update - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.